Moreover, it has also been shown that the loss of PTPN2 may contribute to resistance of chronic myeloid leukemia cells to imatinib through the modulation of PTPN2-dependent signals downstream the BCR-ABL fusion protein12. The gene discussed is PTPN2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.